Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins

Current Opinion in Biotechnology

Volumn 22, Issue 6, 2011, Pages 924-930

  Sánchez Martín, David ^a   Sanz, Laura ^a   Álvarez Vallina, Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL MEDICINE; EX-VIVO; GENETICALLY MODIFIED; HUMAN CELLS; IN-VIVO; LARGE-SCALE PRODUCTION; PURIFIED PROTEIN; THERAPEUTIC AGENTS; THERAPEUTIC PROTEIN; THERAPEUTIC USE; TRANSFER METHOD; VIRAL VECTORS;

CELLS; GENE THERAPY; GENE TRANSFER; MEDICINE; PHYSIOLOGY; PURIFICATION;

ANTIBODIES;

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANGIOPOIETIN 1; BETA GLUCURONIDASE; BETA INTERFERON; BEVACIZUMAB; CARCINOEMBRYONIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROPOIETIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; INTERLEUKIN 12; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY CD3; PARVOVIRUS VECTOR; PLASMINOGEN ACTIVATOR INHIBITOR; RELAXIN; SCATTER FACTOR RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VIRUS VECTOR;

ACUTE LUNG INJURY; ANEMIA; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; BRAIN ISCHEMIA; BREAST CANCER; CANCER INHIBITION; CELL BASED GENE THERAPY; COLON CARCINOMA; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EX VIVO GENE TRANSFER; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA; HEART DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOGENICITY; IN VIVO GENE TRANSFER; LEG ISCHEMIA; LUNG EDEMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MESENCHYMAL STEM CELL; METASTASIS INHIBITION; MUCOPOLYSACCHARIDOSIS TYPE 7; NEURAL STEM CELL; NONHUMAN; PLAGUE; PRION DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA DEGENERATION; SPINAL CORD INJURY; SQUAMOUS CELL CARCINOMA; VIRAL GENE DELIVERY SYSTEM; WEST NILE FEVER;

ANTIBODIES; ANTIBODY FORMATION; GENE THERAPY; GENETIC ENGINEERING; HUMANS; PROTEINS;

EID: 82755187346     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2011.03.001     Document Type: Article

References (73)

1. Zhang Q., Chen G., Liu X., Qian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res 2007, 17:89-99.
2. Reichert J.M., Rosensweig C.J., Faden L.B., Dewitz M.C. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005, 23:1073-1078.
3. Samaranayake H., Wirth T., Schenkwein D., Raty J.K., Yla-Herttuala S. Challenges in monoclonal antibody-based therapies. Ann Med 2009, 41:322-331.
4. Cuesta A.M., Sainz-Pastor N., Bonet J., Oliva B., Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010, 28:355-362.
5. Noel D., Pelegrin M., Marin M., Biard-Piechaczyk M., Ourlin J.C., Mani J.C., Piechaczyk M. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum Gene Ther 1997, 8:1219-1229.
6. Pelegrin M., Marin M., Noel D., Del Rio M., Saller R., Stange J., Mitzner S., Gunzburg W.H., Piechaczyk M. Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Ther 1998, 5:828-834.
7. Noel D., Pelegrin M., Kramer S., Jacquet C., Skander N., Piechaczyk M. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther 2002, 13:1483-1493.
8. Sanz L., Kristensen P., Blanco B., Facteau S., Russell S.J., Winter G., Alvarez-Vallina L. Single-chain antibody-based gene therapy: inhibition of tumour growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther 2002, 9:1049-1053.
9. Sanchez-Arevalo Lobo V.J., Cuesta A.M., Sanz L., Compte M., Garcia P., Prieto J., Blanco F.J., Alvarez-Vallina L. Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer 2006, 119:455-462.
10. Afanasieva T.A., Wittmer M., Vitaliti A., Ajmo M., Neri D., Klemenz R. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther 2003, 10:1850-1859.
11. Fang J., Qian J.J., Yi S., Harding T.C., Tu G.H., VanRoey M., Jooss K. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005, 23:584-590.
12. Watanabe M., Boyer J.L., Crystal R.G. Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum Gene Ther 2009, 20:598-610.
13. Watanabe M., Boyer J.L., Crystal R.G. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumours. Gene Ther 2010, 17:1042-1051.
14. Watanabe M., Boyer J.L., Hackett N.R., Qiu J., Crystal R.G. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumours in immunodeficient mice. Hum Gene Ther 2008, 19:300-310.
15. Ho D.T., Wykoff-Clary S., Gross C.S., Schneider D., Jin F., Kretschmer P.J., Hermiston T.W. Growth inhibition of an established A431 xenograft tumour by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer Gene Ther 2009, 16:184-194.
16. Wang G., Qiu J., Wang R., Krause A., Boyer J.L., Hackett N.R., Crystal R.G. Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther 2010, 17:559-570.
17. Liu X., Wu J., Zhang S., Li C., Huang Q. Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. Cancer Gene Ther 2009, 16:861-872.
18. Vigna E., Pacchiana G., Mazzone M., Chiriaco C., Fontani L., Basilico C., Pennacchietti S., Comoglio P.M. "Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res 2008, 68:9176-9183.
19. Pacchiana G., Chiriaco C., Stella M.C., Petronzelli F., De Santis R., Galluzzo M., Carminati P., Comoglio P.M., Michieli P., Vigna E. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 2010, 285:36149-36157.
20. Nayak S., Herzog R.W. Progress and prospects: immune responses to viral vectors. Gene Ther 2010, 17:295-304.
21. Compte M., Blanco B., Serrano F., Cuesta A.M., Sanz L., Bernad A., Holliger P., Alvarez-Vallina L. Inhibition of tumour growth in vivo by in situ secretion of bispecific anti-CEA×anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007, 14:380-388.
22. Frank R.T., Edmiston M., Kendall S.E., Najbauer J., Cheung C.W., Kassa T., Metz M.Z., Kim S.U., Glackin C.A., Wu A.M., et al. Neural stem cells as a novel platform for tumour-specific delivery of therapeutic antibodies. PLoS ONE 2009, 4:e8314.
23. Riddell S.R., Elliott M., Lewinsohn D.A., Gilbert M.J., Wilson L., Manley S.A., Lupton S.D., Overell R.W., Reynolds T.C., Corey L., et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996, 2:216-223.
24. Fontana R., Bregni M., Cipponi A., Raccosta L., Rainelli C., Maggioni D., Lunghi F., Ciceri F., Mukenge S., Doglioni C., et al. Peripheral blood lymphocytes genetically modified to express the self-tumour antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 2009, 113:1651-1660.
25. Lamers C.H., Willemsen R., van Elzakker P., van Steenbergen-Langeveld S., Broertjes M., Oosterwijk-Wakka J., Oosterwijk E., Sleijfer S., Debets R., Gratama J.W. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117:72-82.
26. Compte M., Cuesta A.M., Sanchez-Martin D., Alonso-Camino V., Vicario J.L., Sanz L., Alvarez-Vallina L. Tumour immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009, 27:753-760.
27. Compte M., Alonso-Camino V., Santos-Valle P., Cuesta A.M., Sanchez-Martin D., Lopez M.R., Vicario J.L., Salas C., Sanz L., Alvarez-Vallina L. Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Ther 2010, 17:745-751.
28. Pereboev A., Borisevich V., Tsuladze G., Shakhmatov M., Hudman D., Kazachinskaia E., Razumov I., Svyatchenko V., Loktev V., Yamshchikov V. Genetically delivered antibody protects against West Nile virus. Antiviral Res 2008, 77:6-13.
29. Skaricic D., Traube C., De B., Joh J., Boyer J., Crystal R.G., Worgall S. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology 2008, 378:79-85.
30. Sofer-Podesta C., Ang J., Hackett N.R., Senina S., Perlin D., Crystal R.G., Boyer J.L. Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun 2009, 77:1561-1568.
31. Van Blarcom T.J., Sofer-Podesta C., Ang J., Boyer J.L., Crystal R.G., Georgiou G. Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Gene Ther 2010, 17:913-921.
32. Zuber C., Mitteregger G., Schuhmann N., Rey C., Knackmuss S., Rupprecht W., Reusch U., Pace C., Little M., Kretzschmar H.A., et al. Delivery of single-chain antibodies (scFvs) directed against the 37/67kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol 2008, 89:2055-2061.
33. Haider H., Jiang S., Idris N.M., Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 2008, 103:1300-1308.
34. Spanholtz T., Maichle A., Niedworok C., Stoeckelhuber B.M., Kruger S., Wedel T., Aach T., Middeler G., Hellwig-Burgel T., Bader A., et al. Timing and targeting of cell-based VEGF165 gene expression in ischemic tissue. J Surg Res 2009, 151:153-162.
35. Toyama K., Honmou O., Harada K., Suzuki J., Houkin K., Hamada H., Kocsis J.D. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp Neurol 2009, 216:47-55.
36. Yu J.X., Huang X.F., Lv W.M., Ye C.S., Peng X.Z., Zhang H., Xiao L.B., Wang S.M. Combination of stromal-derived factor-1alpha and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularization. J Vasc Surg 2009, 50:608-616.
37. Goncalves G.A., Vassallo P.F., dos Santos L., Schettert I.T., Nakamuta J.S., Becker C., Tucci P.J., Krieger J.E. Intramyocardial transplantation of fibroblasts expressing vascular endothelial growth factor attenuates cardiac dysfunction. Gene Ther 2010, 17:305-314.
38. Yang F., Cho S.W., Son S.M., Bogatyrev S.R., Singh D., Green J.J., Mei Y., Park S., Bhang S.H., Kim B.S., et al. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proc Natl Acad Sci U S A 2010, 107:3317-3322.
39. Chen Y.L., Chen P.K., Jeng L.B., Huang C.S., Yang L.C., Chung H.Y., Chang S.C. Periodontal regeneration using ex vivo autologous stem cells engineered to express the BMP-2 gene: an alternative to alveolaplasty. Gene Ther 2008, 15:1469-1477.
40. Sheyn D., Pelled G., Zilberman Y., Talasazan F., Frank J.M., Gazit D., Gazit Z. Nonvirally engineered porcine adipose tissue-derived stem cells: use in posterior spinal fusion. Stem Cells 2008, 26:1056-1064.
41. Chang S.C., Lin T.M., Chung H.Y., Chen P.K., Lin F.H., Lou J., Jeng L.B. Large-scale bicortical skull bone regeneration using ex vivo replication-defective adenoviral-mediated bone morphogenetic protein-2 gene-transferred bone marrow stromal cells and composite biomaterials. Neurosurgery 2009, 65:75-81. discussion 81-73.
42. Kubo S., Cooper G.M., Matsumoto T., Phillippi J.A., Corsi K.A., Usas A., Li G., Fu F.H., Huard J. Blocking vascular endothelial growth factor with soluble Flt-1 improves the chondrogenic potential of mouse skeletal muscle-derived stem cells. Arthritis Rheum 2009, 60:155-165.
43. Kumar S., Nagy T.R., Ponnazhagan S. Therapeutic potential of genetically modified adult stem cells for osteopenia. Gene Ther 2010, 17:105-116.
44. Kumar S., Wan C., Ramaswamy G., Clemens T.L., Ponnazhagan S. Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect. Mol Ther 2010, 18:1026-1034.
45. Shin J.H., Kim K.H., Kim S.H., Koo K.T., Kim T.I., Seol Y.J., Ku Y., Rhyu I.C., Chung C.P., Lee Y.M. Ex vivo bone morphogenetic protein-2 gene delivery using gingival fibroblasts promotes bone regeneration in rats. J Clin Periodontol 2010, 37:305-311.
46. Chen N.K., Tan S.Y., Udolph G., Kon O.L. Insulin expressed from endogenously active glucose-responsive EGR1 promoter in bone marrow mesenchymal stromal cells as diabetes therapy. Gene Ther 2010, 17:592-605.
47. Chen N.K., Wong J.S., Kee I.H., Lai S.H., Thng C.H., Ng W.H., Ng R.T., Tan S.Y., Lee S.Y., Tan M.E., et al. Nonvirally modified autologous primary hepatocytes correct diabetes and prevent target organ injury in a large preclinical model. PLoS ONE 2008, 3:e1734.
48. Campeau P.M., Rafei M., Francois M., Birman E., Forner K.A., Galipeau J. Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther 2009, 17:369-372.
49. Xu J., Qu J., Cao L., Sai Y., Chen C., He L., Yu L. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 2008, 214:472-481.
50. Gregory-Evans K., Chang F., Hodges M.D., Gregory-Evans C.Y. Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol Vis 2009, 15:962-973.
51. Eliopoulos N., Francois M., Boivin M.N., Martineau D., Galipeau J. Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res 2008, 68:4810-4818.
52. Fritz V., Noel D., Bouquet C., Opolon P., Voide R., Apparailly F., Louis-Plence P., Bouffi C., Drissi H., Xie C., et al. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumour. Stem Cells 2008, 26:2981-2990.
53. Hu M., Yang J.L., Teng H., Jia Y.Q., Wang R., Zhang X.W., Wu Y., Luo Y., Chen X.C., Zhang R., et al. Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumour model. BMC Cancer 2008, 8:306.
54. Kim S.M., Lim J.Y., Park S.I., Jeong C.H., Oh J.H., Jeong M., Oh W., Park S.H., Sung Y.C., Jeun S.S. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008, 68:9614-9623.
55. Ren C., Kumar S., Chanda D., Chen J., Mountz J.D., Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 2008, 26:2332-2338.
56. Ren C., Kumar S., Chanda D., Kallman L., Chen J., Mountz J.D., Ponnazhagan S. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 2008, 15:1446-1453.
57. Hong X., Miller C., Savant-Bhonsale S., Kalkanis S.N. Antitumor treatment using interleukin-12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery 2009, 64:1139-1146. discussion 1146-1137.
58. Li Z., Liu Y., Tuve S., Xun Y., Fan X., Min L., Feng Q., Kiviat N., Kiem H.P., Disis M.L., et al. Toward a stem cell gene therapy for breast cancer. Blood 2009, 113:5423-5433.
59. Loebinger M.R., Eddaoudi A., Davies D., Janes S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009, 69:4134-4142.
60. Sims T.L., Hamner J.B., Bush R.A., Fischer P.E., Kim S.U., Aboody K.S., McCarville B., Danks M.K., Davidoff A.M. Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis. J Pediatr Surg 2009, 44:204-210. discussion 210-201.
61. Wang N., Fallavollita L., Nguyen L., Burnier J., Rafei M., Galipeau J., Yakar S., Brodt P. Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. Mol Ther 2009, 17:1241-1249.
62. Sanz L., Santos-Valle P., Alonso-Camino V., Salas C., Serrano A., Vicario J.L., Cuesta A.M., Compte M., Sanchez-Martin D., Alvarez-Vallina L. Long-term in vivo imaging of human angiogenesis: critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels. Microvasc Res 2008, 75:308-314.
63. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
64. Goren A., Dahan N., Goren E., Baruch L., Machluf M. Encapsulated human mesenchymal stem cells: a unique hypoimmunogenic platform for long-term cellular therapy. FASEB J 2010, 24:22-31.
65. Hernandez R.M., Orive G., Murua A., Pedraz J.L. Microcapsules and microcarriers for in situ cell delivery. Adv Drug Deliv Rev 2010, 62:711-730.
66. Garcia-Gomez I., Elvira G., Zapata A.G., Lamana M.L., Ramirez M., Castro J.G., Arranz M.G., Vicente A., Bueren J., Garcia-Olmo D. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther 2010, 10:1453-1468.
67. Meyerrose T.E., Roberts M., Ohlemiller K.K., Vogler C.A., Wirthlin L., Nolta J.A., Sands M.S. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells 2008, 26:1713-1722.
68. Murua A., Orive G., Hernandez R.M., Pedraz J.L. Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transient immunosuppression. J Control Rel 2009, 137:174-178.
69. Choi J.J., Yoo S.A., Park S.J., Kang Y.J., Kim W.U., Oh I.H., Cho C.S. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 2008, 153:269-276.
70. Chen X., Lin X., Zhao J., Shi W., Zhang H., Wang Y., Kan B., Du L., Wang B., Wei Y., et al. A tumour-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008, 16:749-756.
71. Menon L.G., Kelly K., Yang H.W., Kim S.K., Black P.M., Carroll R.S. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009, 27:2320-2330.
72. Kim H.M., Hwang D.H., Lee J.E., Kim S.U., Kim B.G. Ex vivo VEGF delivery by neural stem cells enhances proliferation of glial progenitors, angiogenesis, and tissue sparing after spinal cord injury. PLoS ONE 2009, 4:e4987.
73. Zhang H., Zhu S.J., Wang W., Wei Y.J., Hu S.S. Transplantation of microencapsulated genetically modified xenogeneic cells augments angiogenesis and improves heart function. Gene Ther 2008, 15:40-48.